Cambridge Ion Channel Forum Barry Cross Conference Centre, Babraham Research Campus, Cambridge CB22 3AT
Programme
6 November 2014
12.00
Registration with lunch
13.15
Welcome
13.20
Neurons calling: neurons regulate OPCs differentiation in health and disease Thora K谩rad贸ttir, University of Cambridge
14.20
Novel proof of concept studies demonstrated the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia and lumbosacral radiculopathy Valerie Morisset, Convergence Pharmaceuticals
14.55
Refreshments
15.30
The P2X4 receptor for ATP: function and pharmacology Sam Fountain, University of East Anglia
16.05
A novel selective and orally bioavailable NaV1.8 blocker PF-01247324 attenuates nociception and sensory neuron excitability Liz Payne, Neusentis
16.40
Ion channels and biologics: potent, selective and mechanistically differentiated Nanobodies targeting KV1.3 Tim Dale, Essen BioScience
17.15
Final comments
17.20
Close
Speaker Profiles Tim Dale, Essen BioScience Tim manages Biological Operations for Essen Bioscience at Welwyn Garden City. Tim is a highly experienced industrial pharmacologist and leader with >20 years track record in applied drug discovery. Trained initially as an in vivo pharmacologist, Tim moved into ion channel drug discovery and cell-based assays in 1995 where he learnt manual electrophysiology and subsequently automated patch-clamp and fluorescence screening methods. Tim has applied these and other methods to drug discovery, contributing to the progression of a number of candidate molecules. His focus has included voltage-gated Na+, Ca2+ and K+, Ca2+-activated K+ and TRP channels and has co-authored 20 publications and patents.
Samuel Fountain, Lecturer in Pharmacology, School of Biological Sciences, University of East Anglia Dr Fountain is a pharmacologist with 15 years experience in cardiovascular biology and ion channel function. He obtained a PhD under the supervision of Professor David Beech FMedSci at the University of Leeds, studying voltagegated K+ channels in human vascular smooth muscle. This was followed by a four year postdoctoral position with Professor Alan North FRS at the University of Manchester researching biophysical and pharmacological properties of P2X receptor ligand-gated ion channels for ATP. He established his independent research group following award of a prestigious five year BBSRC David Phillips Fellowship. His research programme focuses on the molecular pharmacology and physiology of purinergic and chemokine receptors in the context of cardiovascular health and disease. His research involves collaboration with basic scientists, industrial partners and clinical colleagues at the Norfolk & Norwich University Hospital.
Thora Káradóttir, University of Cambridge Dr. Káradóttir is a Wellcome Trust Career Developement Research Fellow at the University of Cambridge, UK. Ragnhildur Thóra did her undergraduate degree in Biochemistry at the University of Iceland, but for her postgraduate training she went to University College London, in England, where she entered the Wellcome Trust 4 year PhD Programme in Neuroscience. In 2007 she was awarded a Dorothy Hodgkin Fellowship of the Royal Society, and in 2011 she was awarded a Wellcome Trust Career Development Research Fellowship. Dr. Káradóttir’s current research focus is to understand how neuronal activity can regulate oligodendrocyte precursor cells’ (OPCs) differentiation and (re) myelination.
Liz Payne, Neusentis Liz is a principal scientist and electrophysiologist within the ion channel team at Pfizer Neusentis. During her time at Pfizer, Liz has worked on multiple Ion channel projects and in particular Nav1.8. Prior to joining Pfizer, Liz worked for Novartis and preceding this received her PhD from the University of Bristol studying the pharmacology of voltage gated calcium channels in cerebellar Purkinje cells.
Valeria Morisset, Convergence Pharmaceuticals I am an electrophysiologist with over 15 experience working in the pain field, in academia and industry. I was responsible for ion channel drug discovery programs in the pain and GI area at GlaxoSmithKline. At Convergence I am VP, head of biology for preclinical and clinical programs.
Delegate List First name Aristos Damian Matt James Adam Aline Dimitri Louisa Tim Richard Kim Dominique Mathilde Samuel Kristen Søren Helen
Surname Alexandrou Bell Bridgland-Taylor Button Carpenter Charpentier Chirgadze Christie Dale Davies Dekermendjian Derjean Durand Fountain Frederiksen Friis Hunter
Company Neusentis BioFocus AstraZeneca MedImmune Limited Kymab Limited One Nucleus University of Cambridge Takeda Cambridge Limited Essen BioScience Ltd Xention Limited Lundbeck Ltd Convergence Pharmaceuticals Ltd Convergence Pharmaceuticals Ltd University of East Anglia (UEA) Lundbeck Ltd Biolin Scientific Takeda Cambridge Limited
Antony
Jackson
University of Cambridge Department of Biochemistry
Duncan
Jarman
Cambridge Bioscience Limited
Ali
Jazayeri
Heptares Therapeutics Ltd
Jeff
Jerman
MRC Technology
Clare
Jones
MedImmune Limited
Mike
Jowett
Cambridge Bioscience Limited
Juha
Kammonen
Neusentis
Srinivasan
Kanumilli
Essen BioScience Ltd
Thora
Karadottir
University of Cambridge
E-Chiang
Lee
Kymab Limited
John
Linley
MedImmune Limited
Jia
Liu
Neusentis
Christopher
Lloyd
MedImmune Limited
Guido
Marconi
Autifony Therapeutics Limited
Selina
Mok
Convergence Pharmaceuticals Ltd
Jenna
Montgomery
Takeda Cambridge Limited
Valerie
Morisset
Convergence Pharmaceuticals Ltd
Michael
Morton
AstraZeneca
Ruth
Murrell-Lagnado
University of Cambridge Department of Pharmacology
Sivakumar
Namadurai
University of Cambridge Department of Biochemistry
Jacqui
Naylor
MedImmune Limited
Rob
Newman
Takeda Cambridge Limited
Liz
Payne
Neusentis
Marc
Rogers
Xention Limited
Francois
Rugiero
Convergence Pharmaceuticals Ltd
Sergey
Sitnikov
University of Cambridge
David
Sokal
Takeda Cambridge Limited
Andrew
Southan
BioFocus
Edward
Stevens
Neusentis
John
Stockley
MedImmune Limited
Kathy
Sutton
Xention Limited
SinLih
Tan
University of Cambridge
Simon
Tate
Convergence Pharmaceuticals Ltd
Toni
Taylor
Neusentis
Andrew
Thompson
University of Cambridge Department of Biochemistry
David
Tickle
MRC Technology
Del
Trezise
Essen BioScience Ltd
Mark
Versavel
Convergence Pharmaceuticals Ltd
Louise Wendy Sandra David Anna
Webdale Williams Wilson Witty Wojciechowska-Bason
Xention Limited MedImmune Limited Sophion Convergence Pharmaceuticals Ltd MedImmune Limited